Lisa Beck is a Dermatology and Skin Diseases physician affiliated with University of Rochester Medicine. OpenAlex indexes 449 publications with 27,508 citations (h-index 78); ClinicalTrials.gov lists 10 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Dermatology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Lisa Beck, M.D., is affiliated with University of Rochester Medicine. The public record shows 449 publications with 27,508 citations (h-index 78), centered on Dermatology and Skin Diseases, Asthma and respiratory diseases, Urticaria and Related Conditions. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 29 companies, 2 NIH-funded awards (2012–2026).
- Most recent indexed publication: 2026 · Advances in therapy
- Top research focus: Dermatology and Skin Diseases
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 29 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 24 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 178.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Scratch and Sleep Quantification in Atopic Dermatitis
Sponsor: University of Rochester
Industry payments
Updated 14 Oct 2026
29 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20257 payments$33,595openpaymentsdata.cms.gov ↗
- UCB SAProgram year20252 payments
- Amgen Inc.Program year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
77.4%Interleukin-4 Receptor alpha Antagonist77.4%Dupixent Syringe54%Dupixent Pen46%Part D<11 patientsAnti-infectives
22.6%Azole Antifungal22.6%Ketoconazole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
2 NIH research awards on record, funded 2012–2026 per NIH RePORTER. The latest:
- Biomarker Identification, Viral Susceptibility and Management in S. aureus Colonized AD Patients
University of Rochester
FY2026$462,039U01AI152011 - Biomarker Identification, Viral Susceptibility and Management in S. aureus Colonized AD Patients
University of Rochester
FY2025$462,039U01AI152011 - Biomarker Identification, Viral Susceptibility and Management in S. aureus Colonized AD Patients
University of Rochester
FY2024$462,039U01AI152011
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Observations on emergence of mannitol-use-deficient Staphylococcus aureus.
Microbiology spectrum
Article2026 - Population Pharmacokinetic and Pharmacodynamic Modeling for the Prediction of the Extended Amlitelimab Phase 3 Dosing Regimen in Atopic Dermatitis.
CPT: pharmacometrics & systems pharmacology
Clinical Trial2025 - Improved patient- and caregiver-reported outcomes distinguish tacrolimus 0.03% from crisaborole in children with atopic dermatitis.
Journal of the European Academy of Dermatology and Venereology
Clinical Trial2024
Most-cited works
by citation count (OpenAlex)- 01
- 02Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisArticle2,060 citations2016
- 03Atopic dermatitisArticle1,495 citations2018
- 04Dupilumab Treatment in Adults with Moderate-to-Severe Atopic DermatitisArticle1,412 citations2014
- 05Cytokine modulation of atopic dermatitis filaggrin skin expressionArticle1,090 citations2007
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania